- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective, Single centre
- Study aim: To evaluate the safety and efficacy of early combination therapy involving both antivirals and monoclonal antibody therapy in severely immunocompromised patients with COVID-19 while assessing the outcomes and duration of viral shedding this patient population
- Number of participants enrolled: 48
- Study enrolling from to
- Study includes follow-up for 1.5 years
Study Data
- Adults
- Fragile population
- Immunocompromised host
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
External Links
Other information
Funders:
- Regione Calabria, Italy
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to